Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03745872
Other study ID # 17-0667.cc
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 26, 2017
Est. completion date August 30, 2021

Study information

Verified date January 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prevention study to improve sun exposure behaviors in children after an educational classroom-based intervention.


Description:

This study aims to demonstrate that learning about sun exposure using a more classroom-based intervention will motivate classroom students to reduce exposure at a critical life period and will create lifetime learned sun exposure behaviors. Students' sun exposure behaviors will be assessed prior to the educational intervention. The educational intervention consists of three educational sessions and one lab lesson. At the conclusion of the intervention, students' sun exposure behaviors will be assessed again via a post-intervention questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date August 30, 2021
Est. primary completion date August 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Years to 15 Years
Eligibility Inclusion Criteria: - Any children between grades 4 and 8 enrolled in one of the participating schools. Exclusion Criteria: - No exclusions, but children or their parents may opt out of participating.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Knowledge Assessment
Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.

Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sun Exposure Knowledge Determining children's knowledge of sun exposure risk through a self-completed questionnaire From the administration of the questionnaire to the end of the followup questionnaire, up to 3 years
Primary Sun Exposure Attitudes Determining children's attitude toward sun exposure through a self-completed questionnaire From the administration of the questionnaire to the end of the followup questionnaire, up to 3 years
Primary Sun Exposure Behavior Determining children's behavior toward sun exposure through a self-completed questionnaire From the administration of the questionnaire to the end of the followup questionnaire, up to 3 years
Secondary Mediators of Program Effects: Attitudes Assessing children's attitude toward sun exposure through a self-completed questionnaire During the followup questionnaire, which is given 3 to 4 weeks post intervention, up to three years
Secondary Mediators of Program Effects: Norms Determining children's understanding of social norms regarding tanning and sun protection through a self-completed questionnaire During the followup questionnaire, which is given 3 to 4 weeks post intervention, up to three years
Secondary Mediators of Program Effects: Personal Agency Determining children's understanding of behavioral control regarding sun protection through a self-completed questionnaire During the followup questionnaire, which is given 3 to 4 weeks post intervention, up to three years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study